Chantal van Gils is Vice President, Evidence & Value at SSI Strategy and a senior life sciences strategist with more than 20 years of experience across academia, industry, and CRO environments. A physician-scientist by training, she specializes in designing and delivering integrated evidence strategies that align clinical development with regulatory, HTA, payer, and commercial requirements. Chantal has led over 100 global and regional programs across oncology, rare diseases, and advanced therapies, with deep expertise in real-world evidence, health economic modeling, and market access. She is recognized for translating complex evidence needs into actionable strategies that support regulatory approval, reimbursement success, and long-term commercial value.

Dr Mel Walker is an expert in early commercial strategy, market access, pricing, and reimbursement, with extensive experience guiding companies in integrating payer and HTA requirements into drug development. He helps clients optimize product value from early target product profile (TPP) design through launch and reimbursement, across multiple therapeutic areas. Mel has deep knowledge of European payer and HTA systems, strategic HTA capabilities, and hands-on experience in payer engagement and early advice processes. He has held senior roles at Roche, GSK, and Otsuka, and co-founded BioPharma Futures. Mel regularly chairs international conferences on market access, HTA, and digital health, and has co-authored over 30 research papers and abstracts, as well as two book chapters.